Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
12.79
-0.62 (-4.62%)
At close: Jan 9, 2026, 4:00 PM EST
12.84
+0.05 (0.39%)
After-hours: Jan 9, 2026, 7:45 PM EST
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$193,000
Market Cap
25.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLRZ News
- 2 days ago - Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - GlobeNewsWire
- 5 days ago - Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - GlobeNewsWire
- 8 days ago - As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - GlobeNewsWire
- 12 days ago - Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet - GlobeNewsWire
- 22 days ago - Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses - GlobeNewsWire
- 4 weeks ago - Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program - GlobeNewsWire
- 4 weeks ago - Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - GlobeNewsWire
- 5 weeks ago - From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection - GlobeNewsWire